СОВРЕМЕННАЯ РЕВМАТОЛОГИЯ №2’14
ЛЕКЦИИ
(In Russ.)]. DOI: http://dx.doi.org/10. 14412/1995-4484-2013-1246.
13. Gill MJ, Quisel AM, Rocca P, Walters DT Diagnosis of systemic lupus erythematosus. Am Fam Physician. 2003;68(11):2179—86.
14. Dipti TR, Azam MS, Sattar MH,
Rahman SA. Detection of anti-nuclear antibody by immunofluorescence assay and enzyme immunoassay in childhood systemic lupus erythematosus: experience from Bangladesh. Int J Rheum Dis.
2012;15(1):121—5. DOI: 10.1111/j.1756-185X.2011.01694.x. Epub 2011 Nov 30.
15. Solomon DH, Kavanaugh AJ, Schur PH; American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 2002;47(4):434—44. DOI: http://dx.doi.org/10.1002/art.10561.
16. Sjowall C, Sturm M, Dahle C, et al. Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus. J Rheum. 2008;35(10):1994—2000. Epub 2008 Sep 1.
17. Ardoin SP, Pisetsky DS. Developments in the scientific understanding of lupus. Arthritis Res Ther. 2008;10(5):218. DOI: 10.1186/ar2488. Epub 2008 Oct 10.
18. Isenberg D. Anti-dsDNA antibodies: still a useful criterion for patients with systemic lupus erythematosus. Lupus.
2004;13(11):881—5. DOI: http://dx.doi.org/10.1191/0961203304lu2028oa.
19. Bertsias G, Ioannidis J, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074—82. DOI: 10.1136/ard.2010.130476. Epub 2010 Aug 19.
20. Попкова ТВ, Лисицына ТА. Рекомендации по ведению больных системной красной волчанкой в клинической практике (по материалам рекомендаций Европейской антиревматической лиги — EULAR). Современная ревматология. 2011;(1):4—12. [Popkova TV, Lisitsyna TA. Rekomendatsii po vedeniyu bol'nykh sistem-noy krasnoy volchankoy v klinicheskoy prak-tike (po materialam rekomendatsiy Evropeyskoy antirevmaticheskoy ligi — EULAR). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2011;(1):4—12. (In Russ.)]. DOI: http://dx.doi.org/ 10.14412/1996-7012-2011-645.
21. Madison PJ, Mogavero H, Reichin M. Pattern of clinical disease associated with antibodies to nuclear riboprotein. J Rheum. 1978;5(4):407—11.
22. Hichon CA, Peschken CA. Sm antibodies increase risk of death in systemic lupus ery-
thematosus. Lupus. 2007;16(3):186—94.
23. Насонов Е. Антифосфолипидный синдром. Москва: Литтерра; 2004. 440 с. [Nasonov E. Antifosfolipidnyi sindrom [Antifosfolipidny syndrome]. Moscow: Litterra; 2004. 440 p.]
24. Ho A, Barr SG, Magder LS, Petri M.
A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2350—7. DOI: http://dx.doi.org/10.1002/1529-0131(200110)44:10%3C2350::AID-ART398%3E3.0.CO;2-A.
25. Manson JJ, Ma A, Rogers P, et al. Relationship between anti-dsDNA, anti-nucleosome and anti-alfa-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthritis Res Ther. 2009;11(5):R154. DOI: 10.1186/ar2831.
26. Ng KP, Manson JJ, Rahman A,
Isenberg DA. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum. 2006;55(6):900—4. DOI: http://dx.doi.org/10.1002/art.22356.
27. Sinico RA, Radice A, Ikehata M, et al. Anti-C1q autoantibodies in lupus nephritis. Prevalence and clinical significance. Ann NY Acad Sci. 2005;1050:193-200. DOI: http://dx.doi.org/10.1196/annals.1313.020.
28. Meyer OC, Nicaise-Roland P, Cadoudal N, et al. Anti-G1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus. Arthritis Res Ther. 2009;11(3):R87. DOI: 10.1186/ar2725. Epub 2009 Jun 10.
29. Цанян МЭ, Александрова ЕН, Соловьев СК, Насонов ЕЛ. Антитела к C1q при системной красной волчанке - биологический маркер активности, предиктор развития нефрита и неблагоприятного жизненного прогноза. Научно-практическая ревматология. 2013;51(1):71—5. [Tsanyan ME, Aleksandrova EN, Solovyev SK, Nasonov EL. Anti-C1q antibodies in systemic lupus erythematosus are a biological marker of the activity of nephritis, a predictor for its development and a poor life prognosis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(1):71—5. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2013-1205.
30. Hepbum AL, Narat S, Mason JC.
The management of peripheral blood cytope-nias in systemic lupus erythematosus. Rheumatology (Oxford).
2010;49(12):2243—54. DOI: 10.1093/ rheumatology/keq269. Epub 2010 Sep 7.
31. Giannouli S, Voulgarelis M, Ziakas PD, Tzioufas AG. Anaemia in systemic lupus erythematosus: From pathophysiology to clinical
assessment. Ann Rheum Dis. 2006;65(2):144—8. DOI: http://dx.doi.org/10.1136/ard.2005.041673. Epub 2005 Aug 3.
32. Schur PH. Laboratory evaluation of patients with systemic lupus erythematosus. In: Lahita R. Systemic lupus erythematosus, 5th ed. 2011. P. 629-54. DOI: http://dx.doi.org/10.1016/B978-0-12-374994-9.10034-8.
33. Kuwana M, Kaburaki J, Okazaki Y, et al. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2006;45(7):851-4. DOI: http://dx.doi.org/10.1093/rheumatology/kel0 10. Epub 2006 Jan 17.
34. Vila LM, Alarcon GS, McGwin JrG,
et al. Reveille, Systemic lupus erythematosus in a multiethnic U.S. cohort, XXXVII: Association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. Arthritis Rheum. 2006;55:799-806. DOI: http://dx.doi.org/10.1002/art.22224.
35. Ng WL, Chu CM, Wu AK, et al. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. QJM.
2006 Jan;99(1):37-47. DOI: http://dx.doi.org/10.1093/qjmed/hci155.
36. Dvorkina O, Ginzler EM. Corticosteroid and nonsteroid anti-inflammatory drug use in systemic lupus erythematosus. In: Lahita R. Systemic lupus erythematosus. 5th ed. 2011. P 1045-60. DOI: http://dx.doi.org/ 10.1016/B978-0-12-374994-9.10056-7.
37. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore). 2006;85(3):147-56.
DOI: http://dx.doi.org/10.1097/01. md.0000224709.70133.f7.
38. Murakami M, Tsubata T, Shinkura R,
et al. Acute lupus hemophagocytic syndrome: report of a case. Nefrologia. 2010;30(2):247-51.
39. Gordon C, Jayne D, Pusey C, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus. 2009;18(3):257-63. DOI: 10.1177/0961203308100481.
40. Batnes EV, Narain S, Naranjo A, et al. High sensitivity C-reactive protein on systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus.
2005;14(8):576—82. DOI: http://dx.doi.org/ 10.1191/0961203305lu2157oa.
41. Williams RC, Harmon ME,
Burlingame R, Du Clos TW. Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheum. 2005;32(3):454—61.